Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Lamivudine/raltegravir
Подписчиков: 0, рейтинг: 0
Combination of | |
---|---|
Lamivudine | Reverse-transcriptase inhibitor |
Raltegravir | Integrase inhibitor |
Clinical data | |
Trade names | Dutrebis |
Routes of administration |
Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
KEGG |
Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. It contains lamivudine and raltegravir. It is taken by mouth. Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes. It was approved for medical use in the United States in 2015.
Lamivudine/raltegravir is not available in the United States.
External links
- "Lamivudine mixture with raltegravir". Drug Information Portal. U.S. National Library of Medicine.